SI2350026T1 - S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo - Google Patents

S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo

Info

Publication number
SI2350026T1
SI2350026T1 SI200931004T SI200931004T SI2350026T1 SI 2350026 T1 SI2350026 T1 SI 2350026T1 SI 200931004 T SI200931004 T SI 200931004T SI 200931004 T SI200931004 T SI 200931004T SI 2350026 T1 SI2350026 T1 SI 2350026T1
Authority
SI
Slovenia
Prior art keywords
medicine
manufacture
pyrimidine derivatives
substituted aniline
cdk inhibitors
Prior art date
Application number
SI200931004T
Other languages
English (en)
Slovenian (sl)
Inventor
Ulrich Lucking
Rolf Jautelat
Gerhard Siemeister
Julia Schulze
Philip Lienau
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of SI2350026T1 publication Critical patent/SI2350026T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200931004T 2008-10-21 2009-10-09 S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo SI2350026T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007247 WO2010046035A1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel
EP09778874.9A EP2350026B1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel

Publications (1)

Publication Number Publication Date
SI2350026T1 true SI2350026T1 (sl) 2014-10-30

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931004T SI2350026T1 (sl) 2008-10-21 2009-10-09 S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo

Country Status (38)

Country Link
US (1) US8735412B2 (pl)
EP (2) EP2179991A1 (pl)
JP (1) JP5564054B2 (pl)
KR (1) KR20110069115A (pl)
CN (1) CN102197029B (pl)
AR (1) AR074053A1 (pl)
AU (1) AU2009306733C1 (pl)
BR (1) BRPI0920112A2 (pl)
CA (1) CA2739739C (pl)
CO (1) CO6361926A2 (pl)
CR (1) CR20110210A (pl)
CU (1) CU24052B1 (pl)
CY (1) CY1115590T1 (pl)
DK (1) DK2350026T3 (pl)
DO (1) DOP2011000107A (pl)
EA (1) EA019230B1 (pl)
EC (1) ECSP11010992A (pl)
ES (1) ES2499028T3 (pl)
HN (1) HN2011001019A (pl)
HR (1) HRP20140830T1 (pl)
IL (1) IL211713A (pl)
MA (1) MA32723B1 (pl)
MX (1) MX2011004238A (pl)
MY (1) MY155230A (pl)
NZ (1) NZ592314A (pl)
PA (1) PA8846201A1 (pl)
PE (1) PE20110546A1 (pl)
PL (1) PL2350026T3 (pl)
PT (1) PT2350026E (pl)
RS (1) RS53523B1 (pl)
SA (1) SA109300632B1 (pl)
SI (1) SI2350026T1 (pl)
TN (1) TN2011000199A1 (pl)
TW (2) TWI458716B (pl)
UA (1) UA103500C2 (pl)
UY (1) UY32190A (pl)
WO (1) WO2010046035A1 (pl)
ZA (1) ZA201103727B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
CA2848615C (en) 2011-09-16 2020-02-25 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US20150051232A1 (en) * 2012-03-21 2015-02-19 Bayer Intellectual Property Gmbh Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
ES2691227T3 (es) * 2014-10-16 2018-11-26 Bayer Pharma Aktiengesellschaft Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfoximina
JP2022500388A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1794134A1 (de) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PL2350026T3 (pl) 2014-11-28
SA109300632B1 (ar) 2013-07-04
BRPI0920112A2 (pt) 2015-12-22
AU2009306733A1 (en) 2010-04-29
CN102197029A (zh) 2011-09-21
AR074053A1 (es) 2010-12-22
DK2350026T3 (da) 2014-09-15
TN2011000199A1 (en) 2012-12-17
HN2011001019A (es) 2013-07-01
PE20110546A1 (es) 2011-08-12
CU20110088A7 (es) 2011-12-28
AU2009306733C1 (en) 2016-07-14
EA201100623A1 (ru) 2011-12-30
EP2350026B1 (de) 2014-06-18
MA32723B1 (fr) 2011-10-02
EP2350026A1 (de) 2011-08-03
ECSP11010992A (es) 2011-05-31
TWI458716B (zh) 2014-11-01
MY155230A (en) 2015-09-30
JP2012506391A (ja) 2012-03-15
CA2739739C (en) 2016-12-20
NZ592314A (en) 2013-02-22
TW201444803A (zh) 2014-12-01
HRP20140830T1 (hr) 2014-11-21
MX2011004238A (es) 2011-05-23
CA2739739A1 (en) 2010-04-29
WO2010046035A1 (de) 2010-04-29
TWI496774B (zh) 2015-08-21
IL211713A (en) 2015-04-30
JP5564054B2 (ja) 2014-07-30
PA8846201A1 (es) 2010-05-26
ES2499028T3 (es) 2014-09-26
IL211713A0 (en) 2011-06-30
US8735412B2 (en) 2014-05-27
CU24052B1 (es) 2014-12-26
EP2179991A1 (de) 2010-04-28
CN102197029B (zh) 2014-05-14
CY1115590T1 (el) 2017-01-04
EA019230B1 (ru) 2014-02-28
PT2350026E (pt) 2014-09-12
UA103500C2 (uk) 2013-10-25
CR20110210A (es) 2011-06-08
RS53523B1 (en) 2015-02-27
TW201020237A (en) 2010-06-01
AU2009306733B2 (en) 2015-11-12
CO6361926A2 (es) 2012-01-20
UY32190A (es) 2010-05-31
US20110294838A1 (en) 2011-12-01
ZA201103727B (en) 2014-11-26
KR20110069115A (ko) 2011-06-22
DOP2011000107A (es) 2011-05-15

Similar Documents

Publication Publication Date Title
PL2350026T3 (pl) Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
AU2009276339A8 (en) Pyrimidine compounds, compositions and methods of use
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL207195A0 (en) Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof
IL210412A0 (en) Heterocyclic derivatives and uses thereof
IL210176A0 (en) Substituted pyrimidone derivatives
HK1117164A1 (en) Dicyclic azaalkane derivatives, preparing method and pharmaceutical use thereof
AP2010005390A0 (en) Crystal form of phenylamino pyrimidine derivatives.
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
EP2365809B8 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2351755A4 (en) NEW CRYSTALLINE FORMS OF PEMETREXEDIC ACID AND THEIR PREPARATION
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
HK1162494A1 (en) Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine cdk
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
IL208336A (en) Pyridazinone derivatives, drugs containing them and their uses and process for preparation
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
EP2184277A4 (en) ARYLPYRIMIDINE DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL USES OF THE DERIVATIVES
HK1169110A1 (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors (6--16--2-) akt
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
ZA201105219B (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
ZA201204339B (en) Novel (heterocycle-tetrahydropyridine)(piperazinyl)-1-alcanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alcanone derivatives,and use thereof as p75 inhibitors